GNbAC1

DRUG6 trials

Sponsors

GeNeuro Innovation SAS, GeNeuro SA, GeNeuro Australia PTY Ltd

Conditions

Diabetes Mellitus Type 1Healthy VolunteersMultiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Phase 1

First-in-Human Study With GNbAC1 in Healthy Volunteers

CompletedNCT01699555

GeNeuro Innovation SASMultiple Sclerosis

Start: 2011-07-31End: 2012-08-31Updated: 2020-10-20

Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers

CompletedNCT02452996

GeNeuro Innovation SASHealthy Volunteers

Start: 2015-04-30End: 2015-08-31Target: 21Updated: 2020-10-20

Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers

CompletedNCT03574428

GeNeuro Australia PTY LtdMultiple Sclerosis

Start: 2018-05-08End: 2018-11-02Updated: 2020-10-20

Phase 2

Safety Study of GNbAC1 in Multiple Sclerosis Patients

CompletedNCT01639300

GeNeuro Innovation SASMultiple Sclerosis

Start: 2012-07-31End: 2014-04-30Updated: 2021-02-08

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

CompletedNCT02782858

GeNeuro SAMultiple Sclerosis, Relapsing-Remitting

Start: 2016-04-30End: 2017-12-31Updated: 2020-10-20

Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

CompletedNCT03179423

GeNeuro Australia PTY LtdDiabetes Mellitus Type 1

Start: 2017-06-14End: 2019-05-07Updated: 2020-10-20

Related Papers

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Multiple Sclerosis Journal2021-07-0974 citations

Human endogenous retrovirus and clinical treatments of neurological disease

Proceedings of 6th International Electronic Conference on Medicinal Chemistry2020-11-05

A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env.

2019-07-139 citations

HERV-W-Env Involvement in Human T1D Pathogenesis—New Insights from Two Mouse Models

Diabetes2018-06-221 citations

GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.

2012-11-2951 citations